Company Participation in Investor Conferences - Novavax, Inc. will participate in the Jefferies Global Healthcare Conference on June 4, 2025, from 2:00 to 2:30 p.m. ET in New York, NY [1] - The company will also present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025, from 2:00 to 2:35 p.m. ET in Miami Beach, FL [2] - Webcasts of both events will be available on the company's Events & Presentations page, with replays accessible for 30 days [2] Company Overview - Novavax, Inc. focuses on addressing significant global health challenges through its expertise in vaccines and its technology platform, which includes protein-based nanoparticles and the Matrix-M® adjuvant [3] - The company's growth strategy aims to optimize existing partnerships, expand access to its technology platform through research and development, and pursue organic portfolio expansion in infectious diseases and other areas [3]

Group 1 - Zacks Premium offers various tools for investors, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens to enhance investment confidence [1][2] - The Zacks Style Scores rate stocks based on value, growth, and momentum characteristics, helping investors identify securities with high potential for market outperformance over the next 30 days [2][3] Group 2 - The Value Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales, appealing to value investors [3] - The Growth Score assesses a company's financial health and future outlook by analyzing projected and historical earnings, sales, and cash flow, targeting growth investors [4] - The Momentum Score helps investors capitalize on price trends by evaluating short-term price changes and earnings estimate revisions [5] Group 3 - The VGM Score combines Value, Growth, and Momentum Scores, serving as a comprehensive indicator for investors seeking stocks with attractive value, strong growth forecasts, and promising momentum [6] - The Zacks Rank, based on earnings estimate revisions, has shown significant success, with 1 (Strong Buy) stocks averaging a +25.41% annual return since 1988, outperforming the S&P 500 [8] Group 4 - Novavax, Inc. is a biotechnology company focused on developing vaccines for serious infectious diseases, currently holding a 3 (Hold) Zacks Rank with a VGM Score of B [12] - Novavax has a Momentum Style Score of A, with shares increasing by 8.7% over the past four weeks, and has seen upward revisions in earnings estimates for fiscal 2025 [13]

Core Viewpoint - The S&P 500 has experienced persistent volatility in 2025, leading to cautious investor sentiment, but this environment may present opportunities for significant gains for those willing to take moderate risks [1]. Group 1: Septerna Inc. - Septerna Inc. is a clinical-stage biotechnology firm focused on developing G protein-coupled receptor (GPCR) oral small molecule drug candidates for various diseases [4][6]. - The company has secured a major partnership with Novo Nordisk, which could enhance its growth potential, with an immediate payment of approximately $200 million and a deal potentially worth over $2 billion [5][6]. - Analysts have a consensus price target of $27 per share for Septerna, indicating a potential upside of 184.81% from the current price of $9.48, despite the stock having fallen by about 58% year-to-date [7][4]. Group 2: Intellia Therapeutics Inc. - Intellia Therapeutics is a genome editing firm developing therapies for conditions such as hemophilia and cancers, with promising trial data reported for its ongoing Phase 1 trial [9][10]. - The company has a strong cash position of $707 million as of March 31, 2025, which is expected to fund operations through early 2027 [10]. - The consensus price target for Intellia shares is $36.90, suggesting a potential quadrupling of the stock's current price, with 14 out of 21 analysts rating the stock as a Buy [11]. Group 3: Novavax Inc. - Novavax has received full FDA approval for its protein-based COVID-19 vaccine, unlocking a $175 million milestone payment from Sanofi, positioning it as a non-mRNA option [12][13]. - Despite the approval, the FDA has imposed significant restrictions that may limit the vaccine's availability, contributing to mixed market reactions [13]. - The consensus price target for Novavax shares is $19, indicating a potential upside of 160.63%, with four out of seven analysts rating the stock as a Buy [12][13].

Core Insights - Novavax has received full FDA approval for its COVID-19 vaccine, NUVAXOVID, marking a significant milestone for the company and validating its recombinant protein-based vaccine technology [2] Company Developments - The FDA approval triggers a $175 million milestone payment for Novavax, indicating strong financial implications for the company [2] - The approval comes after years of strategic pivots and navigating bureaucratic challenges, showcasing the company's resilience and commitment to bringing its vaccine to market [2] Industry Context - The approval of NUVAXOVID contributes to the broader landscape of COVID-19 vaccines, highlighting the ongoing competition and innovation within the biotech sector [2]

点击蓝字，关注我们 今日上午港股 1、美图高开15% ，创近7年新高，与阿里合作并获得2.5亿美元战投； 2、万国数据（09698）绩后高开6% ，一季度营收同比增长12%，净利润实现扭亏为盈； 3、三生制药(01530)高开近3% 近日与辉瑞达成重磅交易 进一步验证707商业化出海潜力； 4、高鑫零售(06808)涨超10% 全年扭亏为盈赚4.05亿元 末期息派17港仙； 5、哔哩哔哩-W(09626)绩后涨超3% 首季度毛利润同比增近六成 效果类广告收入取得强劲增长； 6、黄金股集体走高， 地缘冲突升温避险需求提升 国际金价一度涨穿3300美元。 赤峰黄金(06693)涨 6.43%； 招金矿业(01818)涨 超5%，海域金矿投产在即； 山东黄金(01787) 涨4.03% ； 紫金矿业(0289 9) 涨3.51%。 7、泡泡玛特(09992)涨超5%再创新高 ，大摩称Labubu带动新店开业，越南供应链进展超预期； 8、中通快递跌超6% ，Q1毛利率下滑； 9、康方生物(09926)涨超6% 三生制药PD-1双抗出海刷新纪录 公司依沃西战胜K药； 10、老铺黄金(06181)涨超6% 618开门红首 ...

Core Insights - Novavax has received FDA approval for its Covid-19 vaccine, Nuvaxovid, after a delay, but with specific usage restrictions for certain age groups [2][4] - The approval reflects skepticism within federal health agencies regarding vaccines, particularly from appointed leaders [3] - Novavax must conduct additional studies to assess potential links between its vaccine and heart conditions, such as myocarditis [6][7] Group 1: FDA Approval and Restrictions - The FDA approved Novavax's Covid-19 vaccine, limiting its use to individuals aged 65 and older and those aged 12 to 64 with underlying health conditions [2][4] - The approval comes after the vaccine was previously used under emergency authorization since 2022 [4] Group 2: Market Position and Partnerships - Novavax is preparing for commercial delivery of its vaccine in the U.S. this fall, in partnership with Sanofi, following a $1.2 billion licensing deal [8] - The partnership with Sanofi is expected to enhance Novavax's market share in the Covid vaccine sector due to Sanofi's strong distribution capabilities [8] Group 3: Financial Implications - The full approval has triggered a $175 million milestone payment to Novavax from Sanofi, which is significant for the company [9] - Analysts suggest that the narrower approval may not be detrimental, as the 65 and older age group represents a substantial portion of the Covid vaccination demographic [9]

Group 1 - Novavax's COVID-19 vaccine, Nuvaxovid, received full approval from the FDA, leading to a nearly 26% surge in its stock price during pre-market trading [1] - The FDA approved Nuvaxovid for individuals aged 65 and above but restricted its use for those aged 12-64 with underlying health conditions [2] - The approval is based on data from a pivotal late-stage study demonstrating the vaccine's safety and effectiveness [3] Group 2 - Nuvaxovid is now the only non-mRNA-based COVID-19 vaccine available in the U.S., providing an alternative to mRNA vaccines from Moderna and Pfizer [6] - Sanofi acquired exclusive global marketing rights for Nuvaxovid, triggering a $175 million milestone payment upon full approval, along with ongoing tiered royalties on future sales [7] - Novavax faced delays in vaccine approval and launch, impacting its sales during the previous vaccination season, but aims to participate early in the upcoming season [9]

Core Insights - Novavax Inc's stock price surged by 26% to $8.48 following FDA approval of its COVID-19 vaccine, Nuvaxovid, which is protein-based and targets individuals aged 12 to 64 with underlying health conditions [1] Stock Performance - If the gains are sustained, this will be Novavax's highest single-day percentage increase since May, surpassing long-term resistance levels and trading at its highest since March, moving away from the 52-week low of $5.01 recorded on April 10 [2] Options Activity - The options market has seen a significant increase in activity, with NVAX experiencing four times its usual options volume, including 57,000 calls and 13,000 puts. The most active option is the weekly 5/23 9-strike call [4] - Short interest accounts for 28.6% of the stock's available float, indicating that part of the stock's rise may be due to short covering, with an estimated seven days required for shorts to cover their positions at the current trading pace [4]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive employs technology to enhance workflows and has a forward-looking approach to technology adoption [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Novavax Corporate Presentation May 2025 © 2025 NOVAVAX. All rights reserved. Cautionary Note Regarding Forward-Looking Statements This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These forward-looking statements address various matters including Novavax's corporate strat ...